Factive gemifloxacin: Phase III data

In a double-blind Phase III trial in 216 evaluable

Read the full 99 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE